Effects of Topical Antiglaucoma Medications on the Ocular Surface

In this Subject: <a title="Biology/Life Sciences" href="/content/subcat?j_subject=156&j_availability=">Biology/Life Sciences ,&nbsp; <a title="Medicine (General)" href="/content/subcat?j_subject=205&j_availability=">Medicine (General) ,&nbsp; Ophthalmology
By this author: Asbell, Penny A. ;&nbsp; Potapova, Natalia

Purchase options

Article Access Options

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$68.00 plus tax Refund Policy

Abstract:

The side effects of topical antiglaucoma medications and their preservatives range from ocular discomfort to sight-threatening alterations of the ocular surface. Conjunctival hyperemia, decreased tear production and function, and superficial punctate keratitis are among the most common signs seen on routine clinical examination. Squamous cell metaplasia and changes in cell morphology have been demonstrated by impression cytology studies and evaluation of biopsy specimens, and inflammatory effects are documented by the presence of inflammatory markers. The adverse effects of topical antiglaucoma eyedrops interfere with the treatment of glaucoma on two levels: first, the discomfort produced by the eye drops discourages patient compliance; and, second, long-term treatment with eyedrops is associated with a higher failure of filtration surgery. The detailed mechanism of inflammatory response and/or direct toxicity of eye drops has yet to be determined, but it may vary with the different classes of eye drops, different preservatives, and durations of treatments. Upcoming multicenter trials for new antiglaucoma eye drops should specifically evaluate ocular surface effects.

The requested document is freely available to subscribers. Users without a subscription can purchase this article.